Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV-supported projects
R&D areas of work
Next-generation medicines
Products for key populations
Working with regulators
Information for scientists
Malaria online course
Global health compound design webinars
Call for proposals
TPPs & TCPs
Learning resources for scientists
Project of the year award
Computational chemistry
R&D challenges
Access
Products & projects
Product availability maps
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Tool Kits
Injectable Artesunate tool kit
Artesunate rectal capsules tool kit
Seasonal Malaria Chemoprevention tool kit
Access challenges
Partnering
The PDP model
Our partner network
Our donors
Current donors
Past donors
Donate to MMV
Socially responsible agreements
Our clinical centre partners
Our impact
Milestones
Real life stories
Better medicines for children
Gender equity
Global health security
Malaria and COVID-19
Tackling antimicrobial resistance
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
Policies
Diversity at MMV
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
Five species
Parasite lifecycle
Malaria facts & figures
Malaria treatment
History of antimalarials
Newsroom
News & Press Releases
Audio
Media interviews
Speaking of Malaria podcast
Films
Infographics
Interviews
Image slideshows
Publications
Events
MMV Open
Malaria
Libre
About Malaria
Libre
Participate in Malaria
Libre
Malaria
Libre
data repository
MMVSola
About MMVSola
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
COVID Box
About the COVID Box
Supporting information
COVID Box terms and conditions
Archived projects
Pathogen Box
Malaria Box
MMV Open Team
Contact us
Home
Newsroom
Press releases
Press releases
Filter
All
R&D
Donors
General
Open source
Partner
Access & product management
All
R&D
Donors
General
Open source
Partner
Access & product management
26 found
Single-dose Kozenis (tafenoquine) approved for children with
Plasmodium vivax
malaria by Australian Therapeutic Goods Administration
14 Mar 2022
New partnership launched to accelerate elimination of relapsing
P. vivax
malaria that poses a risk to an estimated 2.5 billion people worldwide
14 Jul 2021
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with
Plasmodium vivax
malaria accepted by Australian Therapeutic Goods Administration
08 Jan 2021
MMV supports the launch of the new Fight the Fakes Alliance
07 Dec 2020
Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of
P. vivax
malaria
24 Apr 2020
Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of
P. vivax
malaria
30 Oct 2019
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria
23 Apr 2019
Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of
P. vivax
malaria
21 Sep 2018
Severe malaria case fatality reduced by 96% in pilot project in Zambia led by Transaid, MMV and partners
28 Aug 2018
US FDA approves
Krintafel
(tafenoquine) for the radical cure of
P. vivax
malaria
20 Jul 2018
US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of
P. vivax
malaria
12 Jul 2018
WHO provides first-ever approval for rectal artesunate product for severe malaria
27 Feb 2018
Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children
25 Jul 2017
Three MMV-supported antimalarials listed as essential medicines
16 Jun 2017
Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines
20 Apr 2016
Pyramax® Granules becomes first paediatric antimalarial to receive EMA Article 58 positive scientific opinion
20 Nov 2015
Breakthrough Therapy designation for potential new anti-relapse medicine for malaria
20 Dec 2013
Delivery of child-friendly antimalarial hits the 100 million mark
22 Feb 2012
"SMS for Life" rolled-out nationwide in the United Republic of Tanzania
18 Apr 2011
MMV and Novartis launch Coartem®
Dispersible
20 Feb 2009
MMV and Novartis launch Coartem®
Dispersible
in Africa
15 Feb 2009
Unique collaboration launches a new malaria medicine to save millions of children
27 Jan 2009
First-ever comprehensive report on the antimalarials market in Uganda shows how understanding markets can help improve access to medicines
05 Nov 2008
Unforgettable launch of MMV-MOH Uganda pilot
22 Sep 2008
MoH - MMV: Bold intervention being designed in Uganda to deliver subsidized effective antimalarials
01 Oct 2007
Uganda and MMV explore innovative ways to give patients access to life-saving antimalarials
09 May 2007